Essilor: Procedures for Requesting or Viewing Proxy Information for the Combined Ordinary and Extraordinary Annual Meeting on May 16, 2013
* Reuters is not responsible for the content in this press release.
http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130405:nBw055552a http://www.businesswire.com/news/home/20130405005552/en CHARENTON-LE-PONT, France--(Business Wire)-- Regulatory News: Essilor (Paris:EI) : Shareholders are advised that the Combined Ordinary and Extraordinary Annual Meeting will be held on Thursday, May 16, 2013 at 10:30 am CEST at Palais des Congrès de Paris, 2 place de la Porte Maillot, 75 017 Paris, France. The preliminary notice of meeting, published in the Bulletin des Annonces Légales Obligatoires on April 5, 2013, contains information on the agenda, the proposed resolutions and the procedures for attending and voting. Proxy information may be viewed in the Investors section of the Essilor corporate website at http://www.essilor.com: "Individual Shareholders Information / Annual Shareholders` Meeting". As provided for in articles R.225-88 and R.225-89 of the French Commercial Code, any shareholder may consult the proxy documents and information, as described in article R.225-83 of the French Commercial Code, at Company headquarters (147 rue de Paris, 94220 Charenton-le-Pont, France) or request that such documents be sent to him or her, by writing to Société Générale, Service des Assemblées, 32 rue du Champ de Tir, BP 81236 - 44 312 Nantes Cedex 3, France. About Essilor The world`s leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its corporate mission is to enable everyone around the world to access lenses that meet his or her unique vision requirements. To support this mission, the Company allocates more than €150 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Essilor`s flagship brands are Varilux®, Crizal®, Definity®, Xperio®, OptifogTM and Foster Grant®. It also develops and markets equipment, instruments and services for eyecare professionals. Essilor reported consolidated revenue of approximately €5 billion in 2012 and employs around 50,700 people in some 100 countries. It operates 22 plants, more than 400 prescription laboratories and edging facilities, as well as several research and development centers around the world. For more information, please visit www.essilor.com. The Essilor share trades on the NYSE Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices. Codes and symbols: ISIN: FR FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP. Investor Relations and Financial Communications Phone: +33 (0)1 49 77 42 16 Copyright Business Wire 2013
- Housing, jobs data weaken, but overall economic picture still upbeat
- Target cyber breach hits 40 million payment cards at holiday peak |
- 'Duck Dynasty' anti-gay fallout sparks debate on religion, tolerance
- UPDATE 3-Saab wins Brazil jet deal after NSA spying sours Boeing bid
- Zuckerberg to sell Facebook shares worth about $2.3 billion |